A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan|DRUG: Durvalumab|DRUG: Paclitaxel|DRUG: Capivasertib|DRUG: Anastrozole|DRUG: Fulvestrant|DRUG: Capecitabine
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo Co., Ltd.|Daiichi Sankyo Company, Limited